Dec 27 (Reuters) – The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb’s (BMY.N), opens new tab blockbuster cancer drug, Opdivo.

Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system’s ability to fight cancer by removing its natural brakes.

Like other PD-1 drugs such as Merck’s (MRK.N), opens new tab Keytruda, it was previously available through infusions and patients received it via an intravenous drip in a health office.